Compare Heron Therapeutics Inc (HRTX) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Alliant Energy Corporation — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Alliant Energy Corporation trades at $73.98 (market cap $19.10B). The key difference: Alliant Energy Corporation is far larger — about 208.8× Heron Therapeutics Inc's market cap, and Alliant Energy Corporation pays a 2.89% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | LNT | |
|---|---|---|
Market Cap | $91.46M | $19.10B |
Sector | Health | Utilities |
52-Week High | $1.96 | $78.03 |
52-Week Low | $0.39 | $63.62 |
Enterprise Value | $189.36M | $30.83B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
LNT trades at $73.96, down 1.16% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $78.50. The company reported Q1 2026 EPS of $0.82, beating expectations, and maintains a net income margin of 18.58%. Recent news highlights its $13.4 billion clean energy investment plan aimed at capitalizing on data center demand growth.
The outlook for LNT is positive, supported by steady earnings growth, a strong dividend yield, and strategic investments in renewable energy. Key risks include rising debt levels and exposure to regulatory changes in the utilities sector. Analyst sentiment is bullish with no sell ratings, indicating confidence in the company's long-term growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
